Quantcast

Latest Rituximab Stories

2014-09-01 23:01:09

MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store. Overview of B-cell NHL, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines for DLBCL, FL, MZL and MCL. Dallas, Texas (PRWEB) September 01, 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value will experience moderate growth across six major markets (the US, France, Italy, Germany, Spain and the...

2014-07-31 16:28:44

- IMBRUVICA Net Product Revenue Increased to $109.5 million for the Second Quarter of 2014 - SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended June 30, 2014. Financial Results for the Six Months and Quarter Ended June 30, 2014 Revenue Total revenue for the quarter ended June 30, 2014 increased to $113.0 million from $54.7 million for the quarter ended June 30,...

2014-07-30 12:30:36

Findings presented at the 2014 World Transplant Congress SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system. http://photos.prnewswire.com/prnvar/20100914/PH63692LOGO The...

2014-07-23 16:28:25

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies...

2014-07-14 12:55:18

The Lancet Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology. "The good news is that 5-year survival for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in...

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-11 12:28:56

Marketing Strategies That Educate Payers and Prescribers on Key Benefits of New Drugs Will Maximize Rapid Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., June 11, 2014 /PRNewswire/ -- Decision Resources Group finds that regimens based on Janssen's Velcade are the most commonly prescribed treatments for first-line multiple myeloma (MM), according to surveyed hematological oncologists from France, Germany, Italy and Spain. The exception is the United...

2014-06-10 23:13:54

Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in patients with rheumatoid arthritis on stable methotrexate (MTX) treatment. Birmingham, AL (PRWEB) June 10, 2014 *To see if you qualify for this RA Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance...

2014-06-09 12:26:41

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement,...

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.